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Murine leukemia virus (MLV)-derived vectors are widely used for hematopoietic stem cell (HSC) gene transfer, but
lentiviral vectors such as the simian immunodeficiency virus (SIV) may allow higher efficiency transfer and better
expression. Recent studies in cell lines have challenged the notion that retroviruses and retroviral vectors integrate
randomly into their host genome. Medical applications using these vectors are aimed at HSCs, and thus large-scale
comprehensive analysis of MLV and SIV integration in long-term repopulating HSCs is crucial to help develop improved
integrating vectors. We studied integration sites in HSCs of rhesus monkeys that had been transplanted 6 mo to 6 y
prior with MLV- or SIV-transduced CD34
þ cells. Unique MLV (491) and SIV (501) insertions were compared to a set of in
silico-generated random integration sites. While MLV integrants were located predominantly around transcription
start sites, SIV integrants strongly favored transcription units and gene-dense regions of the genome. These
integration patterns suggest different mechanisms for integration as well as distinct safety implications for MLV versus
SIV vectors.
Citation: Hematti P, Hong BK, Ferguson C, Adler R, Hanawa H, et al. (2004) Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and
progenitor cells. PLoS Biol 2(12): e423.
Introduction
Integration of proviral DNA into the host cell genome is an
essential step in the life cycle of retroviruses. The process
begins after a retrovirus enters the cell and the RNA genome
is reverse transcribed into double-stranded DNA. Preintegra-
tion complexes (PICs) containing linear proviral DNA
associated with several viral and cellular proteins (Bushman
1999) either enter the nucleus of nondividing cells through
the nuclear pores (lentiviruses) or gain access to chromoso-
mal DNA after dissolution of the nuclear membrane during
mitosis (oncoretroviruses). When the PIC associates with the
host chromosome, the virally encoded integrase directs the
insertion of the proviral DNA into the cellular chromosomal
DNA (Hindmarsh and Leis 1999). The provirus is then stably
transmitted to all progeny of transduced cells as an integral
element of the host genome. Beyond its importance to the
reproduction of the virus itself, this distinctive feature of
retroviruses accounts for many of the characteristics asso-
ciated with retroviral infection, including latency and
persistence of infection, insertional mutagenesis, and the
usefulness of retroviruses as vectors for gene therapy.
Engineered replication-defective retroviruses were intro-
duced over 20 y ago and rapidly became attractive tools for
efﬁcient and stable introduction of genes of interest, in
particular into hematopoietic stem cells (HSCs). Retroviral
gene therapy targeting HSCs has been aggressively pursued
because of its potential to treat many congenital and
acquired human diseases. Its therapeutic promise was
convincingly demonstrated in children with X-linked severe
combined immunodeﬁciency (SCID-X1) and adenosine de-
aminase deﬁciency (Aiuti et al. 2002; Hacein-Bey-Abina et al.
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tempered when lymphoproliferative disease developed in two
children who received genetically modiﬁed CD34
þ cells for
treatment of SCID-X1, in association with proviral activation
of the LMO2 transcription factor gene (Hacein-Bey-Abina et
al. 2003). These serious adverse events have galvanized
investigators to further assess the potential risks associated
with gene therapy protocols utilizing retroviral vectors.
For many years, researchers have been aware that retroviral
insertional activation of proto-oncogenes can result in
tumors. Administration of replication-competent oncoretro-
viruses to susceptible mouse strains led to tumor develop-
ment, the result of a high number of repetitive insertion
events in vivo during rapid cell proliferation, with outgrowth
of a clone containing one or more proviruses activating
growth control genes (Dudley 2003). While the possibility of
insertional mutagenesis using replication-defective vectors
has been discussed as theoretically possible (Cornetta et al.
1991), such risks have been estimated to be extremely low
(Moolten and Cupples 1992) based on the assumption that
proviral integration into the genome was random (Cofﬁn et
al. 1997).
With the readily accessible human genome sequence,
mapping studies of retroviral integration sites in cell lines
have uncovered nonrandom integration patterns, when
studied using wild-type HIV, HIV-derived, or murine
leukemia virus (MLV)-derived vectors (Elleder et al. 2002;
Schroder et al. 2002; Laufs et al. 2003; Wu et al. 2003; Mitchell
et al. 2004). However, these integration patterns have not
been investigated in the most relevant primary cells for
hematopoietic gene therapy, namely HSCs. HSC transduction
by retroviral vectors and their subsequent vector-genome
integration patterns can unequivocally be assessed only by
transplanting these cells and analyzing vector-containing cells
in multiple lineages in vivo long-term, since stem and
progenitor cell activity are deﬁned by functional reconstitu-
tion of hematopoiesis in vivo. Interpretation of such studies
may be more complex due to the potential for integration-
speciﬁc impact on engraftment or functional properties of
primitive hematopoietic cells in vivo. However, large-scale
analysis of retroviral integration sites in a relevant long-term
large animal model is critical to fully assess the potential risks
associated with proviral insertion in this population of cells,
prior to implementing new gene therapy trials. These studies
may also provide further insights into mechanisms of
integration targeting and the impact of integration events
on the behavior of hematopoietic cells.
In order to evaluate the integrating vectors currently being
developed for gene therapy applications, we compared the
integration patterns of MLV and simian immunodeﬁciency
virus (SIV) vectors. MLV vectors have been utilized for over a
decade in clinical trials. However, they have a number of
limitations, including inefﬁcient transduction of quiescent
cells and difﬁculty in maintaining stable high-level expression
from tissue-speciﬁc internal genetic control elements. Thus,
lentiviral vectors based on HIV or SIV ‘‘backbones’’ have
been pursued and shown to overcome these limitations, and
are now moving into clinical trials.
Vector-genome junction sequences were retrieved from
mature granulocytes and mononuclear cells (MNCs) from
rhesus macaques transplanted 6 mo to 6 y prior with mo-
bilized peripheral blood (PB) CD34
þ cells transduced with an
MLV- (Schmidt et al. 2002) or SIV-derived vector (Hanawa et
al. 2004), both containing marker genes with no known
impact on proliferation or survival of transduced cells (Wu et
al. 1998). This model represents a unique opportunity to
analyze retroviral insertion patterns in the engrafted progeny
of primitive long-term repopulating cells, without interfer-
ence from confounding factors such as the impact of
transgene expression or an underlying hematopoietic dis-
ease.
Results
Cloning, Sequencing, and Bioinformatic Analysis of
Retroviral Integration Sites
We used a modiﬁcation of the sensitive linear ampliﬁca-
tion-mediated (LAM)-PCR method (Schmidt et al. 2002) to
retrieve and clone the genomic regions adjacent to proviral
integration sites from circulating granulocytes and MNCs
sampled in rhesus macaques engrafted stably long-term,
between 6 mo and 6 y after transplantation of transduced
CD34
þ for the MLV-transduced animals, and 6–7 mo
posttransplantation for the SIV-transduced animals. In our
extensive prior analysis of 46 rhesus macaques, genetic
marking levels and clonal integration patterns are stable by
3–4 mo posttransplantation, and remain stable for up to 6–7 y
(Kiem et al. 2004). This approach uses a frequent-cutting
enzyme to generate average genomic fragments of 80 bp,
thereby circumventing PCR bias against large fragments,
while facilitating ampliﬁcation and cloning. The average
length of all analyzed genomic fragments was 159 bp (median
131 bp, range 30–728 bp).
Owing to the close phylogenetic relationship between
human and rhesus macaques, we were able to directly align
our sequences with the human genome assembly. We
considered a sequence as a genuine retroviral integration
site only if it (a) juxtaposed to the vector long terminal repeat
(LTR), (b) yielded a unique best hit by BLAT software
(University of California, Santa Cruz [UCSC] Genome
Browser, http://genome.ucsc.edu), and (c) showed at least
90% identity to the July 2003 human genome assembly (Kent,
2002; Karolchik et al. 2003). After several analyses using
different cutoffs, we decided to use a conservative alignment
cutoff of 90% in order to include most of the orthologous
regions between human and rhesus genomes, while discard-
ing sequences of technically poor quality. This cutoff
eliminated 5 to 10% of the retrieved sequences, and we
veriﬁed that omission of these sequences with less than 90%
identity from our analysis did not change the overall
distribution of the integration sites (Table S1). Using these
selection criteria, we have retrieved and analyzed 992
independent unequivocal retroviral integration sites (n ¼
491 for MLV [Dataset S1], and n ¼ 501 for SIV [Dataset S2]).
Of the 992 integration sites analyzed, 232 (23%) were
distributed among the four major classes of transposable
repetitive elements, and therefore could not be mapped to a
unique position in the genome. These insertions accounted
for 59 of 491 (12%) and 173 of 501 (34.5%) of the MLV and
SIV integration events, respectively. Human transposon-
derived repeats encompass at least 45% of our genome and
their distribution is highly variable, with density varying
from 2% to 98% depending on the location (Lander et al.
2001).
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We correlated the 760 integration sites (432 for MLV and
328 for SIV) that unequivocally mapped to a unique position
in the genome to the locations of annotated genes, using the
UCSC Genome Browser Reference Sequence (RefSeq) Genes
track, which displays the positions of National Center for
Biotechnology Information mRNA Reference Sequences
(Table 1). We observed that 212 of 432 (49%) of the MLV
integrations and 241 of 328 (73%) of the SIV integrations
landed between the transcription start and stop point of a
RefSeq gene. As a control, we compared the coordinates of
two sets of 1,000 in silico-generated random integration sites,
each containing 432 or 328 coordinates (760,000 total) with
the positions of known genes. Both MLV and SIV insertion
patterns were signiﬁcantly different from the random
integration sites (Figure 1), of which only 32 % were within
RefSeq genes, a percentage identical to the average estima-
tion of the human genome content (25.5%–37.8%, median
31.6%) (Venter et al. 2001).
We next examined whether speciﬁc regions of the tran-
scription units were more likely sites of integration than
others. We analyzed the distribution of the integration events
within the transcription unit by dividing the distance of each
integration site from the transcription start site by the gene
length. The resulting ratio, reported as the total number of
integration events in RefSeq genes for each vector, provides
the percentage of integrations within ten equal sections of
transcription units. While SIV targets the entire transcription
unit with no noticeable preference, 42 of 212 (20%) of the
MLV integration sites that land within RefSeq genes, as
compared 18 of 241 (7%) for SIV, are located within the ﬁrst
one-tenth of the transcription unit, indicating MLV’s clear
predilection for the 59 portion of transcription units (p ¼
0.0002).
MLV Vectors Favor Integration around Transcription Start
Sites, and SIV Vectors Integrate Predominantly within
Transcription Units
To further explore MLV preferential integration in the
vicinity of transcription start sites, we determined the
distance to the nearest 59 and 39 ends of a RefSeq gene for
each integration site. Interestingly, whereas SIV integration
events do not favor locations upstream or downstream of
transcription units (Table 1), 48 of 432 (11%) of the total
MLV integration sites landed within a 10-kb region upstream
of a RefSeq gene, as compared to 5% expected with the
random integration sets (p , 0.0001). The frequency of
insertions within 10 kb downstream of the 39 end is almost
identical for the MLV and the in silico-generated random sets
(5.3% versus 4.8%).
We then looked at the proviral integrations within a 2-kb
window on either side of transcription start sites. This survey
revealed a strong tendency for MLV vectors to integrate close
to transcription start sites, with 46 of 432 (11%) of the total
MLV integration events occurring within 2 kb upstream or
downstream, as compared to 7 of 328 (2%) for SIV (p ,
0.0001). We broadened this analysis to a 60-kb window
centered on transcription start sites (Figure 2). The overall
distribution of the 432 MLV integration events upstream and
downstream of transcription start sites is almost identical
(20% versus 27%, p ¼ 0.02), but their distribution is clearly
nonrandom and favors a 10-kb window centered around
transcription start sites. This pattern is markedly different
from the distribution of SIV sites: Although there is no
predilection for integration in the vicinity of transcription
start sites, there is a strong preference for integration within
transcription units, rather than upstream of them. Of the
SIV-derived sites, 122 of 328 (37%) are within 30 kb
downstream of the transcription start site, while only 30 of
328 (9%) are within 30 kb upstream (p , 0.0001). Taken
together, these data show a distinct integration pattern
between MLV- and SIV-derived vectors (p , 0.00001 using an
omnibus contingency Chi
2 test): While the latter appear to
integrate predominantly within transcription units, MLV
vectors strongly favor integration within a 10-kb window
centered on transcription start sites.
SIV-Derived Vectors Favor Integration within Gene-Dense
Regions of the Genome
In order to ask whether the preferential integration of
SIV vectors within transcription units might be associated
with physical properties of the genome such as gene density,
we analyzed the overall distribution of integration sites. The
highest density of SIV integration sites per Mbp are on
Chromosomes 17, 19, and 22 (0.50, 0.25, and 0.27 respec-
tively), the three most gene-dense chromosomes, with 15, 23,
and 17 genes per Mbp, respectively (Venter et al. 2001).
Since each chromosome is a patchwork of domains with
varying gene density, we determined the number of RefSeq
g e n e sw i t h i n1M b po fe v e r yi n t e g r a t i o ns i t e ’ sL T R
Table 1. MLV and SIV Integration Sites Distribution (Reported to UCSC RefSeq Genes) Compared to In Silico-Generated Random
Integration Sites
MLV (n ¼ 432) SIV (n ¼ 328) In Silico (n ¼ 760,000) Human Genome (%)
Transcription units 49.1%
a,b 73.5%
a 31.6% 31.6
Introns 46.3%
a,b 69.2%
a 30.1% 30.4
Exons 2.8% 4.3%
a 1.5% 1.2
Within 10 kb upstream of genes 11.1%
a,b 3.7% 5.0% –
Within 10 kb downstream of genes 5.3% 4.3% 4.8% –
The random integration sites correspond to two sets of 1,000 sets, each containing 432 or 328 coordinates (760,000 total). Two-sided p-values were obtained by the Chi
2 test.
a p , 0.0001 compared to in silico-generated random integrations.
b p , 0.0001 compared to SIV-derived integrations.
DOI: 10.1371/journal.pbio.0020423.t001
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Retroviral Integration in HSCscoordinate (Figure 3A). While most (84%) of the random
integration sites tended to be within regions of average gene
density (0–10 genes per Mbp), MLV displayed a strong
tendency to integrate within more gene-dense regions. This
was particularly evident for SIV integration sites, 174 of 328
(53%) of which occurred in regions of the genome whose
gene density is higher than 11 genes per Mbp, compared to
149 of 432 (34%) and 17% for the MLV and the in silico,
random sets, respectively. These data point out another
difference between MLV- and SIV-derived vectors, the latter
exhibiting a marked tendency to target gene-rich regions of
the genome (p , 0.00001 using an omnibus contingency
Chi
2 test).
Recent studies have shown that about 30 highly gene dense
clusters, called ‘‘ridges’’ (a loose acronym for ‘‘regions of
increased gene expression’’), are distributed among chromo-
somes. These ridges are characterized by typical expression
levels per gene up to seven times higher than the genomic
average (Caron et al. 2001). This feature is particularly
evident for Chromosomes 3 and 6 (Versteeg et al. 2003).
When looking at the distribution of retroviral integration
sites on Chromosome 6 (Figure 3B), 22 out of the 30 SIV
integration events (73%) fall within this unique ridge, a
region of 20 Mbp (12% of Chromosome 6) with a density of
24 genes per Mbp, corresponding to the major histocompat-
ibility complex region. This tendency to target gene-rich
regions is less obvious for the MLV vector, which had only 7
out of 24 integration sites (29%) within this ridge (p , 0.005).
Of the 22 SIV proviruses within this 20-Mbp ridge, ten were
found clustered within a 2-Mbp, extremely gene-dense region
(62 RefSeq genes per Mbp). Unexpectedly, only two out of
these ten integration sites are inside transcription units,
underscoring the strong tendency of SIV vectors to target
gene-rich regions of the genome even if not within genes.
Another feature of ridges is that they are noticeably enriched
for short interspersed element (SINE), but depleted for long
Figure 1. Comparison of MLV and SIV
Integration Events
Shown are integrations that landed with-
in RefSeq gene introns (arrows) in
comparison to in silico-generated inte-
gration sites (bars). Black indicates MLV
and gray indicates SIV. *p , 0.0001 by a
Chi
2 test.
DOI: 10.1371/journal.pbio.0020423.g001
Figure 2. Distribution of MLV and SIV
Integration Sites within a 60-kb Window
Centered on Transcription Start Sites
The vertical arrow points to 0 kb. Each
gray bar corresponds to the percentage
of SIV integration sites within a 5-kb
interval, and black bars correspond to
the percentages of MLV integration sites
in a 5-kb interval. The distribution of a
set of 65,000 in silico-generated random
integration sites is represented by the
dashed line.
DOI: 10.1371/journal.pbio.0020423.g002
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Retroviral Integration in HSCsinterspersed element (LINE) repeats (Versteeg et al. 2003).
This correlation between SINE repeat density, GC content,
and gene density has been previously reported (Bernardi et
al. 1985) and may account for our observation of over-
representation of integration events in SINE versus LINE
elements, with 119 of 501 (24%) of the SIV set of integration
sites being within SINE repeats.
Common Integration Sites Differ between SIV- and MLV-
Derived Vectors
Given their distinct patterns of integration, we compared
identiﬁed common integration sites of MLV and SIV
vectors. Using the deﬁnition of a common integration site
as two or more proviruses integrated within a transcription
unit (Suzuki et al. 2002), we have identiﬁed 40 genes
targeted more than once by MLV and/or SIV vectors (Table
S2). Of the RefSeq genes targeted by MLV and SIV vectors,
16 of 199 (8%) and 19 of 222 (9%), respectively, were hit at
least twice, and ten genes were identiﬁed as common
integration sites because they harbor both MLV and SIV
proviruses. These genes have been targeted two times (n ¼
32), three times (n ¼ 6), ﬁve times (n ¼ 1), and seven times (n
¼ 1). Among these 40 genes, seven are known to be involved
in oncogenic translocations: ARHGEF12, MDS1, MKL1, MSF,
HMGA2, RAD51L1, and RUNX1. Seven independent inte-
gration events have been identiﬁed in MDS1, predominantly
within the second intron, 20–180 kb upstream of the ﬁrst
intron of EVI1.
Discussion
A better understanding of retroviral integration patterns
has evolved due to the availability of the complete murine
and human genome sequences. Prior mapping studies have
been performed in cell lines or in primary cells cultured
short-term in vitro. However, integration site patterns may be
cell type–dependent, for instance, if gene activity impacts
integration site selection (Schroder et al. 2002), or if speciﬁc
integrations facilitate engraftment and long-term contribu-
tion to hematopoiesis. Our aim was to provide a compre-
hensive comparative analysis of integration sites distribution
of MLV- and SIV-derived vectors in long-term repopulating
HSCs. Nonhuman primates have been shown to closely
predict results in human transplantation and gene therapy
clinical protocols (Donahue and Dunbar 2001) and thus
represent the best currently available approach to generate
information with relevance to design of future human clinical
trials.
MLV-derived retroviruses are currently the most widely
used vectors in clinical gene transfer protocols. Reports of
proto-oncogene activation by replication-defective MLV
vectors in mice and humans mandate more detailed evalua-
tion of their potential for insertional mutagenesis. Separating
the impact of overexpressing a growth-altering transgene
from the insertional events themselves is particularly im-
portant to assess in primary repopulating HSCs. The main
limitation of murine oncoretroviruses as gene therapy
Figure 3. Distribution and Location of
Integration Sites Relative to Chromosomal
Gene Density
(A) Distribution of MLV and SIV inte-
gration sites relative to gene density
within a 1-Mbp window compared to in
silico-generated random integration
sites. Each bar corresponds to the per-
centage of integration sites within the
corresponding gene density region.
(B) Location of MLV and SIV integration
sites and gene density on human Chro-
mosome 6. MLV and SIV integrations
were aligned to Chromosome 6 (ob-
tained from the UCSC custom annota-
tion track feature) and shown in relation
to RefSeq gene density (blue). 73% of the
SIV integration events are within the 20-
Mbp unique ridge of Chromosome 6,
compared to 29% for MLV. Distance
between thick black bars is 20 Mbp;
centromere is represented by the black
circle.
DOI: 10.1371/journal.pbio.0020423.g003
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Retroviral Integration in HSCsvectors is the requirement that cells pass through mitosis in
order for the PIC to reach the nucleus and integrate. Since
lentiviruses can transduce noncycling cells, lentivirus-based
vectors have been actively developed and a clinical trial using
these vectors has commenced. A detailed analysis of
lentivector integration patterns is essential to assess the risk
of insertional mutagenesis of these vectors compared to MLV
vectors.
Although HIV-derived vectors can enter Old World
monkey cells, they encounter a block prior to reverse
transcription that is mediated by the dominant repressive
factor TRIM5a, a component of cytoplasmic bodies (Stremlau
et al. 2004), and thus are very inefﬁcient at transducing
nonhuman primate cells (An et al. 2000; Horn et al. 2002).
Lentiviral vectors derived from SIV have been generated
(Hanawa et al. 2004; Negre and Cosset 2002) and are useful
for preclinical testing in nonhuman primates. SIV vectors
may also be used to transduce human cells, and offer a
number of potential advantages over HIV vectors for
eventual clinical applications, such as lack of seroconversion
to HIV positivity after exposure.
Only limited information exists regarding the rhesus
monkey genome, but paleontological and genomic sequence
data suggests that Macaca mulatta is 92.5%–95% identical to
the humans at a DNA level (Page and Goodman 2001; Stewart
and Disotell 1998). Moreover, the human and macaque
karyotypes are virtually identical, with near absence of
interchromosomal rearrangements and no detectable seg-
ments of nonhomology in euchromatic regions (Best et al.
1998; Muller and Wienberg 2001). We believe that this
evolutionary information, combined with the characteristics
of the sequences obtained in our study, validates our use of
the human genome sequence to localize rhesus genomic
insertion sites.
Analysis of SIV integration shows a striking tendency to
integrate within transcription units (73% of the mapped
integration events), but no propensity toward integration in
any speciﬁc region of the transcription units, in contrast to
MLV vectors. Although we did not observe regional hot
spots for SIV integration, as previously reported in cell lines
for HIV (Schroder et al. 2002), we instead noted the
clustering of integrations within gene-rich regions. This
penchant for integrating in so-called ridges may offer clues
to a speciﬁc mechanism of integration. Loops of chromatin
extending away from chromosome territories are frequently
observed on the major histocompatibility complex locus of
Chromosome 6, the ridge shown in Figure 3B, especially
when transcription is induced (Mahy et al. 2002; Volpi et al.
2000). These data suggest that the formation of decondensed
chromatin territories might be driven by transcription
(Chubb and Bickmore 2003) to establish a nuclear environ-
ment accessible to transcription factors (Gilbert et al. 2004)
and, therefore, to lentivira lP I C s .T h i sh y p o t h e s i si s
corroborated by the fact that genes targeted by SIV vectors
tend to be more highly expressed in human CD34
þRho
lo
cells, as compared to the total set of 33,000 expressed
sequences analyzed on a standard expression array (Figure
S1). Interestingly, functional analysis of genes identiﬁed as
targets for SIV insertion using the Gene Ontology classi-
ﬁcation (Ashburner et al. 2000) and the EASE bioinformatics
software (Hosack et al. 2003) shows a statistically signiﬁcant
overrepresentation of genes coding for transcription factors
and nuclear proteins (Figure S2), suggesting either these
genes are more concentrated in targeted areas of the
genome or they share common genomic motifs or cellular
proteins.
This striking tendency was not observed with the MLV-
derived set of integration sites. While the ratio of MLV
integration sites within transcription units was signiﬁcantly
higher than expected compared to in silico-generated
random integration sites, the MLV proviruses displayed a
unique and speciﬁc afﬁnity for the region surrounding the
transcription start site of annotated genes. The ﬁnding that
among the 491 MLV integration sites, only 12% are within
SINEs or LINEs may support the fact that MLV inserts into 59
regulatory elements where insertions of transposable ele-
ments are probably strongly selected against. This also
indicates tethering between some transcription factor(s) and
MLV PIC protein(s).
These observations, consistent with previous comparative
analyses in vitro (Wu et al. 2003; Mitchell et al. 2004), likely
reﬂect the vectors’ distinct mechanisms for accessing DNA
and integrating, and may have implications for the relative
risk of insertional mutagenesis. While replication-competent
oncoretroviruses have been widely used to identify genes
involved in cancer (Dudley 2003), insertional oncogenesis has,
to our knowledge, never been clearly reported after lentiviral
infection. Both vectors have drawbacks: MLV vector integra-
tions near the 59 ends of genes may be more likely to disrupt
transcriptional control and result in dysregulated expression
of potentially oncogenic gene products, while SIV vector
insertions within transcription units might be more likely to
result in frame shifts or other events abrogating production
of the normal gene product. Thus, the possibility that SIV
vectors are less likely than MLV vectors to induce tumori-
genesis needs to be carefully evaluated in relevant animal
models.
A large number of genes were identiﬁed with two or more
integration events, and thus were deemed common integra-
tion sites, including ten genes that had both MLV and SIV
integrations. This suggests either that these genes are
particularly susceptible to integration events due to open
chromatin or other factors that favor both types of viruses, or
that integration events in these particular genes alter
expression and favor engraftment and long-term contribu-
tions to hematopoiesis. However, the most striking ﬁnding
was the occurrence of seven independent hits by MLV in the
ﬁrst two introns of the MDS1 gene, whereas MDS1 was not
found in the SIV dataset of integration sites. MDS1 is adjacent
to the EVI1 locus, which has been implicated as a retrovirally
activated proto-oncogene in a number of murine leukemo-
genesis studies (Bartholomew et al. 1989; Bordereaux et al.
1987; Morishita et al. 1988; Li et al. 2002). This unexpected
and highly nonrandom clustering raises several questions
since recent mapping analyses in cell lines did not report any
common integration site (Wu et al. 2003). This suggest that
proviral insertion near a proto-oncogene (MDS1/EVI1) may
occur at a much higher frequency than previously expected.
Studies are ongoing to better understand the causes and
consequences of retroviral integration within this genomic
locus.
It is important to stress that the very long-term follow-up
of a large cohort of nonhuman primates, including all
animals in the current study, has revealed completely normal
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Retroviral Integration in HSCshematopoiesis and lack of any progression towards neoplasia
(Kiem et al. 2004). All animals have stable polyclonal
hematopoiesis from transduced cells without any progression
toward oligoclonality. Despite the nonrandom nature of
integration and the possible targeting of certain proto-
oncogenes, the use of replication-defective MLV or SIV
vectors expressing nontransforming transgenes in the setting
of one or very few integrants per cell still likely carries a very
low risk of oncogenesis (Baum et al. 2003). Design of safer
vectors including insulating elements to decrease the risk of
activation of adjacent genes, development of targeted
integration systems, or use of novel vectors with different
integration patterns, should allow continued progress toward
safe and effective gene therapy. However, for serious
disorders such as SCID, even current MLV vectors are likely
justiﬁed.
Materials and Methods
Rhesus macaque autologous transplantation model. Rhesus mac-
aques were handled in accordance with the guidelines set by the
Committee on Care and Use of Laboratory Animals of the Institute
of Laboratory Animal Resources (National Research Council 1985).
Protocols were approved by the Animal Care and Use Committee of
the National Heart, Lung, and Blood Institute. Details of mobi-
lization, transduction, and transplantation were previously pub-
lished (Hanawa et al. 2004; Hematti et al. 2003; Takatoku et al. 2001;
Wu et al. 2000). Animals were mobilized with stem cell factor (SCF)
and granulocyte colony-stimulating factor for ﬁve doses, and
underwent apheresis on day 5. CD34
þ cells were enriched from
mobilized PB by immunoabsorption and transduced for 96 h with
either amphotropic MLV vectors LNL6 and G1Na containing the
neomycin resistance gene (n ¼ 22) (Miller and Buttimore 1986), or
for 48 h with amphotropic SIV vector containing the green ﬂuorescent
protein gene (n ¼ 3) (Hanawa et al. 2004). All transduction cultures
were carried out in the presence of 100 ng/ml Flt3 ligand, 100 ng/ml
SCF, and either 20 ng/ml interleukin-3 and 50 ng/ml interleukin-6 (n
¼ 12), or 100 ng/ml megakaryocyte growth and development factor
(n ¼ 10 MLV animals and all SIV animals). All animals received cells
transduced on ﬂasks coated with Retronectin (TaKara, Shiga, Japan).
In addition, two MLV animals also received cells transduced on
autologous marrow stromal cells (Wu et al. 2000). Cells were
reinfused intravenously following 1,000 rads of total body irradi-
ation. PB samples were collected at a minimum of 6 mo after
transplantation from three animals receiving SIV-transduced cells
and 22 receiving MLV-transduced cells. MNCs were isolated by
density gradient centrifugation over lymphocyte separation medium
(Organon Teknika, Durham, North Carolina, United States), and
granulocytes were obtained as previously described (Tisdale et al.
1998).
Cloning of the integration sites by LAM-PCR. LAM-PCR and
cloning of insertion site vector genomic fusion sequences was
performed as described (Hanawa et al. 2004; Schmidt et al. 2002)
using 59-linker cassettes and 39-LTR primers designed speciﬁcally for
MLV- or SIV-based vectors (Hanawa et al. 2004) (Table S3).
Amplicons of junctions between genomic regions and 59-LTRs were
puriﬁed from agarose gels and cloned with the TOPO TA cloning kit
(Invitrogen, Carlsbad, California, United States). Cycle sequencing
was performed using an ABI Prism Genetic Analyzer 3100 (Applied
Biosystems, Foster City, California, United States). Sequences were
analyzed using Lasergene software (Dnastar, Madison, Wisconsin,
United States).
Creation of a control set of in silico-generated integration sites. For
statistical comparison to the integration site sets, we computationally
generated 1,000 sets of integration sites. For MLV, we made 1,000
datasets, each containing 432 randomly selected genomic coordi-
nates; for SIV, we made 1,000 datasets of 328 points each. All human
chromosome sequences were concatenated into a single long
sequence. We used the random number generator function in Perl
to pick a number between 1 and the total number of nucleotides in
the human genome (3,098,026,039), then identiﬁed this position in
the concatenated sequence and correlated this position back to its
chromosomal origin. If this coordinate fell within a sequencing gap, a
new number was picked. We performed an ANOVA on the in silico-
generated integration sites to demonstrate that 1,000 random sets
were sufﬁcient (unpublished data).
Genomic analysis of the retroviral and in silico-generated
integration sites. We used a bioinformatic pipeline (Crawford et al.
2004) to map the position of each retroviral and in silico-generated
integration site relative to 20,623 National Center for Biotechnology
Information mRNA RefSeqs aligned by the UCSC Genome Browser.
For each integration site, we calculated the distance to the nearest 59
and 39 end of a RefSeq gene. We disregarded cases in which RefSeq
mRNAs aligned only partially to the genome. Genomic location of all
LTR coordinates are available through the UCSC Genome Browser
Custom Tracks (available at http://research.nhgri.nih.gov/projects/
Dunbar/May2004/). Two-sided p values were obtained using the Chi
2
test.
Functional clustering and over-representation analysis of targeted
genes. Genes identiﬁed as targeted by retroviral insertion were
analyzed for signiﬁcant functional clusters of genes using the EASE
bioinformatics software (http://david.niaid.nih.gov/david/ease.htm).
This software was used to rank functional clusters by statistical
overrepresentation of individual genes in speciﬁc categories relative
to all genes in the same category. The functional clusters used by
EASE were derived from the Gene Ontology classiﬁcation system
(http://www.geneontology.org).
Supporting Information
Dataset S1. MLV-Derived Integration Site Sequences (FASTA Format)
Found at DOI: 10.1371/journal.pbio.0020423.sd001 (78 KB TXT).
Dataset S2. SIV-Derived Integration Site Sequences (FASTA Format)
Found at DOI: 10.1371/journal.pbio.0020423.sd002 (60 KB TXT).
Figure S1. Relative Expression of Genes with Identiﬁed MLV and SIV
Integrations, Using Data from Human CD34
þRho
lo Cells
Found at DOI: 10.1371/journal.pbio.0020423.sg001 (38 KB PDF).
Figure S2. Gene Ontology Categories Statistically Overrepresented in
the Genes Targeted by SIV-Derived Vector
Found at DOI: 10.1371/journal.pbio.0020423.sg002 (16 KB PDF).
Table S1. Comparison of Retroviral Integration Sites Distribution
within Transcription Units
Found at DOI: 10.1371/journal.pbio.0020423.st001 (12 KB PDF).
Table S2. RefSeq Genes Targeted More than Once by SIV, MLV, or
Both Retroviral Vectors
Found at DOI: 10.1371/journal.pbio.0020423.st002 (18 KB PDF).
Table S3. Primers Used for the LAM-PCR Experiments
Found at DOI: 10.1371/journal.pbio.0020423.st003 (8 KB PDF).
Accession Numbers
The retroviral integration site sequences larger than 50 bp discussed
in this paper have been deposited in GenBank (http://www.ncbi.nlm.-
nih.gov/Genbank/) under the accession numbers AY728482 to
AY728804 for SIV, and AY733679 to AY734083 for MLV.
LocusLink ID numbers (http://www.ncbi.nlm.nih.gov/LocusLink/) for
the genes discussed in this paper are ARHGEF12 (23365), EVI1 (2122),
HMGA2 (8091), LMO2 (4005), MDS1 (4197), MKL1 (57591), MSF
(10801), RAD51L1 (5890), RUNX1 (861), and TRIM5a (85363).
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